BioInvent Terminates Current BI-505 Phase II Study
Lund, Sweden (Press Release) – BioInvent International (STO:BINV) announces that it has decided to terminate its current clinical Phase II study with BI-505 in multiple myeloma. The decision follows BioInvent’s review and discussion with the US Food & Drug Administration (FDA), who put BI-505 on full clinical hold in November 2016.
The terminated trial, which was performed in collaboration with Penn Medicine, targeted a specific population of multiple myeloma patients undergoing autologous stem cell transplantation with high-dose melphalan.
About BioInvent
BioInvent International AB (OMXS: BINV) is focused on developing a first-in-class and best-in-class pipeline of antibody immunotherapeutics against cancer. The Company’s clinical programmes include BI-1206, currently in a Phase I/II for non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, BI-505 for multiple myeloma, and TB-403, in cooperation with Oncurious, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour associated macrophages (TAMs). BioInvent works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials.
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 4.45 p.m. CET, on 9 December, 2016.
Source: BioInvent.
Related Press Releases:
- Active Biotech Announces First Patient Dosed In Phase 1b/2a Study Of Tasquinimod Use In Treatment Of Multiple Myeloma
- FDA Lifts Clinical Hold On MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 In Multiple Myeloma
- Kleo Pharmaceuticals Announces Orphan Drug Designation For KP1237 In Multiple Myeloma
- Oncopeptides Starts The Phase 2 PORT Study Comparing Peripheral Versus Central Administration Of Melflufen And Dexamethasone In Multiple Myeloma
- Cellectar Reports Data On CLR 131 Phase 2 CLOVER-1 Study In Triple Class Refractory Multiple Myeloma Patients